CompletedNCT00222794
Atomoxetine for negative symptoms and quality of life in schizophrenia
About this title
Read the official source — NCT00222794Medication studyAges 18–65United States
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- PittsburghSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateNovember 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 66
- Sponsor
- University of Pittsburgh
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00222794
- Official title
Show the full official title
A Randomized, Parallel Group, Double Blind, Placebo Controlled, Clinical Trial of Augmentation With Atomoxetine for the Treatment of Negative Symptoms in Patients With Schizophrenia and Schizoaffective Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Pittsburgh
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Pittsburgh, a university.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine (Strattera).
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
